Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-06-10

Investigating the use of autonomously replicating plasmid vectors for cystic fibrosis gene therapy

Objective



The aim of the research project is to study the use of plasmids containing mammalian origins of replication for gene therapy of cystic fibrosis (CF). Previous reports from Dr. College's group have demonstrated the feasibility of using non-replicating plasmid/liposome complexes for CF gene therapy in vivo. Replicating versus non-replicating plasmids containing different reporter genes or the CFTR gene will be tested to assess whether autonomous replication improves the efficiency and duration of gene expression in vitro and in vivo. The test system will be optimised using plasmids containing viral origins of replication but since plasmids that encode viral transforming proteins are not suitable for human gene therapy trials, we will also generate plasmids that contain some of the recently identified mammalian origins of replication. Plasmid replication assays will be performed in vitro using murine and human cultured epithelial cells. Plasmids will be introduced into cells by electroporation, liposomes or calcium phosphate precipitation. Once the replicating plasmids have been tested for their relative transfection and expression efficiencies in vitro, they will be tested in vivo for correction of the C1- channel defect in CF mice.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Call for proposal

Data not available

Funding Scheme

Data not available

Coordinator

Aristotle University of Thessaloniki
EU contribution
No data
Address
Analytical Chemistry Lab
54006 Thessaloniki
Greece
Total cost
No data